Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | WebDisclosure

Basculer en Français

9475	Companies
185452	Keywords
117793	Articles
99303	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

PRESS RELEASE

published on 12/19/2024 at 22:05, 11 months 16 days ago

Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025
Protagonist Therapeutics to present company overview at 43rd Annual J.P. Morgan Healthcare Conference. Highlights late-stage peptides in clinical development

Clinical Development Biopharmaceutical Protagonist Therapeutics J.P. Morgan Healthcare Conference Peptides
BRIEF

published on 12/09/2024 at 22:10, 11 months 26 days ago

Protagonist Therapeutics Reveals Promising Rusfertide Study Results at ASH 2024

Rusfertide Polycythemia Vera Phase 2 REVIVE Hematocrit Control ASH 2024
BRIEF

published on 12/09/2024 at 22:10, 11 months 26 days ago

Protagonist Therapeutics révèle des résultats prometteurs pour son étude sur le rusfertide à l'ASH 2024

Rusfertide Polycythémie Vraie Phase 2 REVIVE ASH 2024 Contrôle De L'hématocrite
PRESS RELEASE

published on 12/09/2024 at 22:05, 11 months 26 days ago

Protagonist Reports Final Results From Rusfertide Phase 2 REVIVE Study Showing Durable Hematocrit Control at the ASH 2024 Annual Meeting
Protagonist Therapeutics announced positive final data from rusfertide Phase 2 REVIVE study for treating polycythemia vera, presented at ASH 2024

Protagonist Therapeutics Rusfertide Polycythemia Vera Hematocrit Control REVIVE Study
BRIEF

published on 11/22/2024 at 13:35, 1 year ago

Protagonist Therapeutics to Engage at Evercore ISI HealthCONx Conference

Clinical Trials Protagonist Therapeutics Conference Participation Evercore ISI HealthCONx Biopharmaceutical Development
BRIEF

published on 11/22/2024 at 13:35, 1 year ago

Protagonist Therapeutics participera à la conférence Evercore ISI HealthCONx

Essais Cliniques Thérapeutique Protagoniste Participation À La Conférence Evercore ISI HealthCONx Développement Biopharmaceutique
PRESS RELEASE

published on 11/22/2024 at 13:30, 1 year ago

Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024
Protagonist Therapeutics to participate in fireside chat at 7th Annual Evercore ISI HealthCONx Conference on Dec 3-5, 2024. Company's CEO, Dinesh V. Patel, to discuss latest developments

Biopharmaceutical Fireside Chat Protagonist Therapeutics Evercore ISI HealthCONx Conference Dinesh V. Patel
BRIEF

published on 11/21/2024 at 22:10, 1 year ago

Protagonist Therapeutics Nominates PN-881 for Immune-Mediated Skin Disorders

Protagonist Therapeutics IL-17 Antagonist PN-881 Skin Diseases Phase I Trials
BRIEF

published on 11/21/2024 at 22:10, 1 year ago

Protagonist Therapeutics nomme le PN-881 pour le traitement des troubles cutanés à médiation immunitaire

Thérapeutique Protagoniste Antagoniste De L'IL-17 PN-881 Maladies De La Peau Essais De Phase I
PRESS RELEASE

published on 11/21/2024 at 22:05, 1 year ago

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Protagonist Therapeutics announces selection of PN-881, an oral peptide interleukin-17 antagonist, as a development candidate for immune-mediated skin diseases. IND enabling studies ongoing with Phase I expected in Q425

Protagonist Therapeutics IL-17 Antagonist PN-881 Oral Peptide Immune-mediated Skin Diseases

Accesswire

Published on 12/05/2025 at 02:35, 10 hours 49 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 10 hours 54 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 12 hours 24 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 14 hours 19 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 14 hours 24 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 13:00, 24 minutes ago

Zentra Group plc: Posting of Notice of Annual General Meeting
Published on 12/05/2025 at 13:00, 24 minutes ago

Form 8.3 - Zürcher Kantonalbank: Cicor Technologies Ltd.
Published on 12/05/2025 at 12:05, 1 hour 19 minutes ago

Cango Inc. Announces November 2025 Bitcoin Production and Mining Operations Update
Published on 12/05/2025 at 12:00, 1 hour 24 minutes ago

CGTN：Strengthening cultural ties: Peng Liyuan, Brigitte Macron visit Beijing People's Art Theatre
Published on 12/05/2025 at 12:00, 1 hour 24 minutes ago

Iute Group: Successful Issue of Additional EUR 2025/2030 Bonds – Circulating Volume Increased to EUR 160 Million

Les Echos

Published on 12/05/2025 at 08:45, 4 hours 39 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 4 hours 39 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 4 hours 42 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 19 hours 9 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 19 hours 24 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE